Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NCX-701. NicOx.

Girish P Joshi1

  • 1University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9068, USA. girish.joshi@utsouthwestern.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|August 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional Analgesia for Truncal Surgeries: Reply.

Anesthesiology·2026
Same author

Society for Ambulatory Anesthesia Position Statement on Risk Assessment and Prophylaxis for Prevention of Venous Thromboembolism After Ambulatory Surgery: A Simplified Approach.

Anesthesia and analgesia·2026
Same author

Importance of early postoperative mobilization: comprehensive review.

BJS open·2026
Same author

Pain management after elective caesarean section under neuraxial anaesthesia: an updated systematic review and procedure-specific postoperative pain management (PROSPECT) recommendations.

Anaesthesia·2026
Same author

Prolonged Fasting and Patient-Centered Outcomes: When Science Meets Common Sense.

Anesthesia and analgesia·2026
Same author

Pain management after open thoracotomy 2025: procedure-specific postoperative pain management (PROSPECT) recommendations.

Anaesthesia·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

NCX-701, a novel nitric oxide-releasing paracetamol derivative, is being developed to treat inflammation and pain. This promising compound is currently in phase III clinical trials for efficacy and safety evaluation.

Area of Science:

  • Pharmacology
  • Drug Development
  • Pain Management

Background:

  • Paracetamol (acetaminophen) is a widely used analgesic and antipyretic.
  • Inflammation and pain are significant global health concerns.
  • Nitric oxide (NO) plays a role in inflammatory processes.

Purpose of the Study:

  • To develop a novel therapeutic agent for inflammation and pain.
  • To evaluate NCX-701, a nitric oxide-releasing derivative of paracetamol.

Main Methods:

  • NCX-701 is a nitric oxide-releasing derivative of paracetamol (acetaminophen).
  • The compound is currently undergoing phase III clinical trials.

Main Results:

  • Clinical trial data is pending.

Related Experiment Videos

  • Efficacy and safety profiles are under investigation.

    • Conclusions:

    • NCX-701 represents a potential new treatment strategy for inflammatory conditions and pain.
    • Further clinical trial results will determine its therapeutic utility.